PHILADELPHIA and LONDON, April 16 /PRNewswire-FirstCall/ -- Today, The Thomson Corporation (NYSE: TOC; TSX: TOC) announced that it has acquired Newport Strategies, Inc., a leading provider of competitive intelligence for the pharmaceutical industry. Terms of the transaction were not disclosed.
Newport content complements the extensive competitive intelligence information for global pharmaceutical companies currently offered by Thomson. "Using Newport products in conjunction with our existing industry-leading portfolio of information solutions will allow drug makers to make more effective strategic decisions throughout the product life cycle," said Bob Cullen, President & CEO of Thomson Scientific & Healthcare.
Newport offers comprehensive databases and consulting solutions to help drug manufacturers maximize profits in an era of rapidly increasing generic competition. The world's top generic pharmaceutical companies rely on Newport's Horizon Global intelligence system to find business development and licensing opportunities, target products for internal development, and identify strategic suppliers of active pharmaceutical ingredients. Leading pharmaceutical innovators turn to Newport's Vision CI for analysis of impending generic competition, patent challenges and active pharmaceutical ingredient sourcing systems.
Current Newport CEO and Founder, Jean Hoffman, expressed similar enthusiasm saying, "We have great confidence that Newport's capabilities and intelligence combined with the Thomson global reach and leadership in the pharmaceutical industry will bring great benefit to our customers." Newport Strategies will become part of the scientific business within the Thomson Scientific and Healthcare market group.
About Newport Strategies
Newport develops and markets cutting-edge systems that deliver the earliest and most reliable source of global intelligence on competition for launched pharmaceutical products. Innovator, generic and specialty pharmaceutical companies worldwide use Newport's systems and expert confidential consulting to predict competition, optimize product lifecycles, target and develop new business opportunities and source more effectively. Newport is the pioneer in interpreting how active pharmaceutical ingredient development predicts and impacts competition for products in global markets. The company validates and analyzes intelligence on every launched product gathered through its worldwide industry network.
About The Thomson Corporation and Thomson Scientific
The Thomson Corporation (http://www.thomson.com/), with 2003 revenues of $7.6 billion, is a global leader in providing integrated information solutions to business and professional customers. Thomson provides value-added information, software tools and applications to more than 20 million users in the fields of scientific research and healthcare, law, tax, accounting, financial services, higher education, reference information, and corporate training and assessment. With operational headquarters in Stamford, CT, Thomson has approximately 39,000 employees and provides services in approximately 130 countries. The Corporation's common shares are listed on the New York and Toronto exchanges (NYSE: TOC; TSX: TOC).
Thomson scientific information solutions can be found at http://www.thomson.com/scientific and include, ISI Web of Knowledge(SM)- facilitating discovery by offering seamless navigation to high-quality, multidisciplinary journal, patent, and Web content, evaluation tools, and bibliographic management products (EndNote(R)); Delphion Research-providing access to full- text patent documents from the world's leading patent authorities; Derwent World Patents Index(R)-the most comprehensive database of value-added patent documents; Techstreet- offering a wide variety of engineering codes and standards; and BIOSIS Previews(R)-the world's most comprehensive reference database for life science research.
The Thomson Corporation
CONTACT: Rodney Yancey, Manager, Corporate Communications of ThomsonScientific, +1-215-386-0100, ext. 1396, firstname.lastname@example.org; or GeneGartlan, Director of Investor Relations of The Thomson Corporation,+1-203-328-9485, email@example.com